학술논문

506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors
Document Type
article
Source
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2051-1426